Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.

O'branski EE, Ware RE, Prose NS, Kinney TR.

J Am Acad Dermatol. 2001 May;44(5):859-61.

PMID:
11312437
2.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

3.

Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.

Altura RA, Wang WC, Wynn L, Altura BM, Altura BT.

J Pediatr. 2002 May;140(5):565-9.

PMID:
12032523
4.

Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.

de Montalembert M, Bégué P, Bernaudin F, Thuret I, Bachir D, Micheau M.

Arch Dis Child. 1999 Nov;81(5):437-9.

5.

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Blood. 2004 Mar 15;103(6):2039-45. Epub 2003 Nov 20.

6.

Hydroxyurea in very young children with sickle cell anemia is not a cure-all.

Powars DR.

J Pediatr. 2001 Dec;139(6):763-4. No abstract available.

PMID:
11743496
7.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

8.

Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.

Chaine B, Neonato MG, Girot R, Aractingi S.

Arch Dermatol. 2001 Apr;137(4):467-70.

PMID:
11295927
9.

[Longitudinal melanonychia induced by hydroxyurea therapy].

Neynaber S, Wolff H, Plewig G, Wienecke R.

J Dtsch Dermatol Ges. 2004 Jul;2(7):588-91. German.

PMID:
16281621
10.

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P.

J Pediatr. 1996 Oct;129(4):559-65.

PMID:
8859263
11.

Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea.

Wilson S.

Ann Intern Med. 2000 Dec 5;133(11):925-6. No abstract available.

PMID:
11103075
12.

Hydroxyurea for sickle cell anemia.

Bachmeyer C, Aractingi S, Lionnet F.

N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. No abstract available.

PMID:
18609755
13.

Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia.

Zargari O, Kimyai-Asadi A, Jafroodi M.

Pediatr Dermatol. 2004 Nov-Dec;21(6):633-5.

PMID:
15575845
14.

Hydroxyurea for the treatment of sickle cell anemia.

Platt OS.

N Engl J Med. 2008 Mar 27;358(13):1362-9. doi: 10.1056/NEJMct0708272. Review. No abstract available.

PMID:
18367739
15.

Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.

Huang Y, Ananthakrishnan T, Eid JE.

Am J Hematol. 2003 Oct;74(2):125-6.

16.

Malignancies in sickle cell disease patients treated with hydroxyurea.

Ferster A, Sariban E, Meuleman N; Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea.

Br J Haematol. 2003 Oct;123(2):368-9. No abstract available.

PMID:
14531924
17.

Are we underestimating the leukemogenic risk of hydroxyurea.

Al-Jam'a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG.

Saudi Med J. 2002 Nov;23(11):1411-3.

PMID:
12506308
18.

When should hydroxyurea be used for children with sickle cell disease?

Mueller BU.

Pediatrics. 2008 Dec;122(6):1365-6. doi: 10.1542/peds.2008-1058. No abstract available.

PMID:
19047256
19.

Hydroxurea and sickle cell disease: Its been a long, long time coming.

Scott JP.

Pediatr Blood Cancer. 2010 Feb;54(2):185-6. doi: 10.1002/pbc.22340. No abstract available.

PMID:
19908298
20.

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.

de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R.

J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):313-8.

PMID:
9256830

Supplemental Content

Support Center